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Abstract: Not all pseudogenes are transcriptionally silent as previously thought. Pseudogene
transcripts, although not translated, contribute to the non-coding RNA pool of the cell that regulates
the expression of other genes. Pseudogene transcripts can also directly compete with the parent
gene transcripts for mRNA stability and other cell factors, modulating their expression levels.
Tissue-specific and cancer-specific differential expression of these “functional” pseudogenes has
been reported. To ascertain potential pseudogene:gene interactions in HIV-1 infection, we analyzed
transcriptomes from infected and uninfected T-cells and found that 21 pseudogenes are differentially
expressed in HIV-1 infection. This is interesting because parent genes of one-third of these
differentially-expressed pseudogenes are implicated in HIV-1 life cycle, and parent genes of half of
these pseudogenes are involved in different viral infections. Our bioinformatics analysis identifies
candidate pseudogene:gene interactions that may be of significance in HIV-1 infection. Experimental
validation of these interactions would establish that retroviruses exploit this newly-discovered layer
of host gene expression regulation for their own benefit.
Keywords: pseudogenes; HIV-1; differential gene expression; transcriptome; RNASeq
1. Introduction
Pseudogenes are considered relics of once-functional genes that have lost the ability to code for
proteins. They arise due to mutations, frame-shifts and gene duplication events, where the duplicated
gene loses transcriptional elements (like promoters and enhancers) necessary for gene expression [1].
Irrespective of how they are created, pseudogenes are traditionally assumed to be transcriptionally
silent. However, microarray studies show that 2%–20% of pseudogenes are quantifiably expressed
[1–3]. Tissue-specific expression of pseudogenes hints at their possible functional importance in those
tissues [4,5]. Pseudogenes are also differentially expressed in diseases, notably cancer [6–12].
We are only beginning to understand the implications of pseudogene expression for
cellular well-being. Pseudogenes can regulate the expression of parent genes by the following
mechanisms [1]: (i) antisense pseudogene transcripts can pair with a sense parent transcript, altering
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the parent gene mRNA levels [13,14]; (ii) pseudogene transcripts are sometimes processed to produce
small interfering RNAs that silence the parent gene [15,16]; and (iii) pseudogene transcripts can
form competitive endogenous RNA (ceRNA) that competes with the parent gene transcripts for
the shared pool of mRNA stability factors and miRNA [17–20]. Tumor suppressor gene PTEN,
for example, is post-transcriptionally regulated by microRNAs that target transcripts of both PTEN
and its pseudogene PTENP1. Yet, overexpression of the PTENP1 3′ UTR recovers PTEN mRNA
levels, highlighting the functional role of pseudogene PTENP1 transcripts in regulating parent-gene
mRNA abundance levels [20]. Moreover, transcriptional networks are reported to be cross-regulated
with ceRNA networks, suggesting that pseudogene-derived transcripts play an integral role in
regulating cellular gene expression [21]. Pseudogene-derived endogenous siRNA can also regulate
the expression of genes other than its parent gene [12]. In cancer, pseudogenes have been shown
to affect the expression of non-parent genes as well, such as tumor suppressor gene MGA, when
integrated into their promoter regions [9]. By contributing substantially to the small-RNA pool of a
cell, pseudogenes may regulate the expression of their parent gene, as well as other genes.
The majority of pseudogenes in humans are “processed”, i.e., they are created when
a reverse-transcribed mRNA is re-integrated into the genome, often on chromosomes different from
the parent gene [1,22,23]. Thus, these “processed” pseudogenes lack introns and contain poly-A
tails. They also have direct repeats at the 3′ and 5′ ends that likely participate in the genome
re-integration step [1,22,24]. However, how are these processed mRNA transcripts re-integrated back
into the genome? Some long interspersed elements (LINEs) code for reverse transcriptase that makes
the cDNA copy of mRNAs, possibly contributing to the generation of the processed pseudogenes
[9,25,26]. Thus, retroviruses, such as HIV-1, by carrying viral reverse transcriptase and integrase to the
infected cells, may create new pseudogenes and alter the expression of existing pseudogenes [27,28].
Carlton et al. find evidence for the generation of a processed pseudogene during retroviral infection
and speculate that viral reverse transcriptase is involved in the process [28]. It is thus likely
that pseudogene:gene interactions and pseudogene-derived endogenous non-coding RNA constitute
another dimension of virus-host interactions. The impact of non-coding RNAs on HIV-1 replication
and pathogenesis has already been discussed elsewhere [29], such as the role of host-induced antiviral
microRNA in limiting the progression of viral infection [30].
In this study, we investigate differential expression of pseudogenes in HIV-1 infection by
comparing the transcriptomes of infected and uninfected T-cells seven days post-infection. By
identifying parent and other genes that show sequence similarity to these pseudogenes, we predict
candidate pseudogene:gene interactions that may be relevant to HIV-1 infection. We further
analyze publicly-available transcriptomic data collected at 12 h and 24 h post-HIV-1 infection to
identify time-course changes in the expression of pseudogenes and their parent genes. Our results
demonstrate that pseudogenes are active participants in host-pathogen interactions, and their role in
modulating host gene expression should be investigated further.
2. Materials and Methods
2.1. Cells
The human T-cell line H9 was obtained from the NIH AIDS Research and Reference Reagent
Program (Catalog Number 87) [31] and propagated in RPMI 1640 medium (Gibco) supplemented
with 10% fetal bovine serum (HyClone) and 1% 100X Antibiotic-Antimycotic (Gibco). The NL4-3
strain of HIV-1 was obtained from the NIH AIDS Research and Reference Reagent Program (Catalog
Number 9489), and the virus was prepared by transfection of 293T cells. 293T cells were purchased
from ATCC and propagated in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% bovine calf
serum (HyClone).
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2.2. HIV-1 Infection
To generate transcriptomic data, we infected 5× 106 H9 T-cells with 300 ng p24Gag NL43 strain
of HIV-1 using a spinfection protocol (multiplicity of infection > 1): infected cells were incubated at
37 ◦C for 15 min and then centrifuged at 1200 rpm for 2 h at 33 ◦C, followed by a further half-hour
incubation at 37 ◦C and three rounds of washing with RPMI. The infected cells were then replenished
with fresh medium and incubated at 37 ◦C for seven days. Then, 3× 106 uninfected H9 T-cells were
used as the control and incubated for 7 days in conditions identical to the infected T-cells (37 ◦C,
5% CO2). Cellular RNA from infected and uninfected cells was extracted for sequencing 7 days
post-infection using Qiagen’s RNeasy Mini Kit.
2.3. RNA Sequencing
Paired-end (150 bp × 2) RNASeq data were generated using the Illumina HiSeq sequencing
platform. The uninfected sample generated 82 million paired-end reads (24 Gbp) with a mean
fragment size of 377 bp, and the infected sample generated 76 million reads (23 Gbp) with a mean
fragment size of 361 bp. Illumina adaptors were removed using Trimmomatic Version 0.3, and
low-quality reads were dropped using fastq_quality_filter [32]. Ribosomal RNA was depleted, and
poly-A RNA was selected prior to sequencing. The sequence data generated were of high quality.
The average quality score for the forward reads was >34, and that for the reverse reads was >33
(a Q-score of 30 is considered optimal). The transcriptomics data are available at the NCBI’s Gene
Expression Omnibus (GEO) database, via Accession Number GSE70785.
2.4. Pipeline to Identify Differentially-Expressed Pseudogenes
The filtered reads were mapped to the human reference transcriptome using Tophat2 Version
2.0.11 [33]. The human reference genome (fasta file: Homo_sapiens.GRCh37.57.dna.toplevel.fa.gz,
indexed using Bowtie2 Version 2.2.1 [34]) and the most recent human gene model (Gene Transfer
Format (GTF) file: Homo_sapiens.GRCh37.75.gtf) were downloaded from Ensembl. More than 90%
of reads from the uninfected and the infected sample mapped to the human reference transcriptome.
The mapped reads were then supplied to the Cuffdiff program of Cufflinks (Version 2.2.0) to quantify
gene expression, as well as to calculate the log2 fold change in gene expression due to HIV-1
infection [35]. Cuffdiff reports gene expression in FPKM (fragments per kilobase of transcript per
million mapped reads).
To avoid false positives due to noise in measuring very low expression levels, we limited
ourselves to genes with expression >0.1 FPKM in both infected and uninfected cells, a threshold
widely used for reliable detection of transcripts in RNASeq data [36–38]. The 16,243 mRNA
transcripts fulfilling this criteria were further pruned to only those that showed at least a 4-fold
increase or decrease in gene expression due to infection (i.e., a log2 fold change in expression
>2 or <−2). We focused on fold change in gene expression, because this quantity is comparable across
genes with different basal expression levels. This resulted in 493 transcripts with at least a 4-fold
change in expression, of which 46 are annotated as pseudogenes in Ensembl based on GENCODE
(ENCyclopedia Of DNA Elements- genes and gene variants) annotations [26].
We then computed the p-values and false discovery rate (FDR) for these 46
differentially-expressed pseudogenes as follows: the 16,243 genes with expression level >0.1
FPKM in both infected and uninfected cells had an average log2 (fold change in expression) of−0.037
(µ) with a standard deviation (σ) of 0.819 (the log fold change distribution is normally distributed;
Supplementary Figure S1). Using this µ and σ, we calculated z-scores for the pseudogene change
in gene expression as z = (x − µ)/s, where x is the log2 (fold change). p-values for the two-sided
test were determined as the cdf of the normal distribution, and the FDR (Q-value) was calculated
using the qvalue function of R [39]. The computational pipeline to identify differentially-expressed
pseudogenes is outlined in Figure 1.
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Comparing against GENCODE 
gene set annotations 
p-value < 0.01 and FDR < 0.25 
21 differentially-expressed pseudogenes 
Figure 1. Computational pipeline to identify differentially-expressed pseudogenes from
transcriptomic data. The transcriptomic data collected from HIV-1 infected and uninfected H9
T-cells 7 days post-infection were mapped to the human reference transcriptome after quality control
analysis. Differentially-expressed pseudogenes were identified following several stringent filtering
steps that are the accepted standard in the field: at least >4-fold change in expression, p-value < 0.01
and FDR < 0.25.
2.5. Bioinformatics Analysis of Candidate Pseudogenes
Human proteins matching the translated pseudogene sequence were identified by BLASTX
against the GENCODE/Ensembl database using a cutoff E-value of 10−4. BLASTX hits that were
uncharacterized novel protein coding genes are not reported. cDNAs (transcripts/splice variants)
matching pseudogene sequences were identified using BLASTN against the Ensembl cDNA database
using a cutoff E-value of 10−4 and sequence identity of >90%. cDNA hits for uncharacterized genes
and other pseudogenes were ignored.
2.6. Analyses of Publicly-Available Transcriptomic Data
We obtained transcriptomes from HIV-1-infected cells 12 h and 24 h post-infection from the
Gene Expression Omnibus database (GEO ID: GSE53993) [40]. The study authors infected human
T-cell line SUP-T1 (obtained from the American Type Culture Collection) with the HIV-1 strain LAI
(obtained from the NIH AIDS Research and Reference Reagent Program). The authors submitted the
RNASeq data to the GEO database for the following: from HIV-1-infected cells 12 h post-infection
(3 replicates), mock infected cells 12 h post-infection (3 replicates; mock infection with SUP-T1
cell-conditioned medium), HIV-1-infected cells 24 h post-infection (3 replicates) and mock infected
cells 24 h post-infection (2 replicates) [40]. We analyzed these RNASeq datasets as described above:
quality control followed by mapping the reads to human reference transcriptome using Tophat2 and
quantifying gene expression using Cuffdiff to determine the log2 fold change in gene expression.
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This generated 9 sets of gene expression comparisons at the 12-h time point (3 replicates of Mock
transcriptomes compared to 3 replicates of HIV-1 infection transcriptomes: a total of 9 comparisons)
and 6 sets of gene expression comparisons at the 24-h time point (2 replicates of Mock × 3 replicates
of HIV-1 infection transcriptomes). These 15 transcriptomics datasets had 14–23 million paired-end
reads each, with a 73%–88% overall read mapping rate to the reference human transcriptome.
Supplementary Table S2 lists the log2 fold change in gene expression at 12 h and 24 h post-infection
for the pseudogenes and their parent genes.
3. Results
Using a p-value < 0.01 as a cutoff, we identified 13 pseudogenes as significantly over-expressed
and 17 as significantly under-expressed in HIV-1-infected T-cells (Table 1). Using an FDR cutoff of
0.25, as previously used for exploratory gene expression analyses [41,42], we further narrowed the
number of differentially-expressed pseudogenes to 21 (eight over-expressed and 13 under-expressed;
shaded rows in Table 1). Most of the over-expressed pseudogenes are processed (Table 1). We also
find several uncharacterized pseudogenes as differentially expressed (pseudogene names with prefix
RP followed by a number).
Table 1. Differentially-expressed pseudogenes in HIV-1 infection 7 days post-infection. Pseudogene
expression is measured from RNASeq data as fragments per kilobase of transcript per million mapped
reads (FPKM). Pseudogenes with a p-value < 0.01 and FDR < 0.25 are shaded and are deemed
differentially expressed.
Pseudogene Type Expression in Expression in log2 p-value Q-valueUninfected T-Cells HIV-1 Infected T-Cells (Fold Change)
A. Over-expressed
DUTP1 Processed 0.159 2.321 3.869 1.85e-06 0.0012
RP1-89D4.1 Processed 0.200 1.377 2.782 0.0006 0.0696
RP11-720N19.1 Processed 0.102 0.676 2.722 0.0007 0.0824
UBE2FP1 Processed 1.277 7.716 2.595 0.0013 0.1183
RP11-170L3.6 Processed 0.312 1.887 2.595 0.0013 0.1183
MTATP8P2 Processed 2.744 16.526 2.59 0.0013 0.1193
RP11-265N6.3 Processed 0.106 0.617 2.536 0.0017 0.1348
MTND4P15 Unprocessed 0.362 2.097 2.535 0.0017 0.1348
IFNL3P1 Unprocessed 0.128 0.632 2.305 0.0042 0.2537
RP11-44M6.3 Processed 0.255 1.235 2.275 0.0048 0.2693
CTD-2611O12.6 Processed 0.183 0.882 2.266 0.0049 0.2736
HMGB3P24 Processed 0.11 0.504 2.191 0.0065 0.3153
AOC4P Unprocessed 0.126 0.546 2.121 0.0084 0.3688
B. Under-expressed
RP11-380G5.3 Processed 1.131 0.103 −3.463 2.868e-05 0.0103
ZNF137P Unprocessed 1.203 0.141 −3.092 0.0002 0.0353
RP11-114F3.5 Processed 0.924 0.113 −3.034 0.0003 0.0415
SCML2P2 Processed 0.955 0.119 −3.003 0.0003 0.0439
ANTXRLP1 Unprocessed 1.507 0.207 −2.865 0.0006 0.0686
HNRNPA3P6 Processed 0.966 0.138 −2.812 0.0007 0.078
RP1-224A6.8 Processed 0.903 0.129 −2.808 0.0007 0.0787
AC010733.5 Processed 3.683 0.555 −2.731 0.001 0.1026
RP11-411B10.4 Unprocessed 0.943 0.152 −2.632 0.0015 0.1284
RP11-490K7.4 Processed 2.187 0.358 −2.613 0.0017 0.1345
KLHL2P1 Unprocessed 0.692 0.113 −2.611 0.0017 0.1348
RP11-471L13.3 Processed 1.6 0.263 −2.608 0.0017 0.1348
CTD-2008A1.2 Unprocessed 1.652 0.276 −2.58 0.0019 0.1457
GUSBP2 Unprocessed 1.124 0.217 −2.375 0.0043 0.2551
RP11-1166P10.1 Unprocessed 0.766 0.154 −2.311 0.0055 0.2849
AKR7A2P1 Processed 0.46 0.1 −2.199 0.0083 0.3665
ADAMTS7P4 Unprocessed 1.06 0.234 −2.182 0.0088 0.3744
3.1. Pseudogenes Derived from Over-Expressed Genes
Over-expressed genes are more likely to form processed pseudogenes [43]. In our analysis,
we find that several differentially-expressed pseudogenes are derived from highly-expressed genes:
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MTATP8P2, MTND4P15, RP1-89D4.1, RP11-380G5.3, AC010733.5. It is likely that these pseudogenes
are observed as differentially expressed largely due to fluctuations in the expression of their
parent genes.
To investigate the putative function of differentially-expressed pseudogenes that are not derived
from over-expressed protein-coding genes, we identified human proteins (Table 2; BLASTX hits
against GENCODE using a cutoff E-value of 10−4) and transcripts/splice variants (Table 3; BLASTN
hits against the Ensembl cDNA database using a cutoff E-value of 10−4 and sequence identity of
> 90%) that are similar to these pseudogene transcripts or their translated products.
Several pseudogenes have their parent genes as the best (and sometimes the only) BLASTX or
BLASTN hit (Tables 2 and 3). A pseudogene may have a regulatory function if its expression correlates
(positively or negatively) with that of its parent or other similar genes.
Table 2. BLASTX hits of differentially-expressed pseudogenes. Only hits to known protein-coding
genes with E-value < 10−4 are shown. “fc” denotes fold change in gene expression; “Mock” represents
gene expression in uninfected T-cells; and “HIV” denotes gene expression in HIV-1-infected T-cells
7 days post-infection.
Pseudogene Chromosome log2(fc) BLASTX Hits Chromosome Mock HIV log2(fc)
A. Over-expressed
DUTP1 3 3.869 DUT 15 181.046 128.614 −0.812
UBE2FP1 3 2.595 UBE2F 2 17.448 20.262 0.216
MTATP8P2 2 2.59 MT-ATP8 MT 1.3e+05 1.5e+05 0.144
MTND4P15 9 2.535 MT-ND4 MT 3.8e+04 3.6e+04 −0.07
RP1-89D4.1 11 2.782 RPS24 10 6416.6 5334.27 −0.267
RP11-720N19.1 17 2.722 MSANTD3 9 9.694 9.455 −0.036
RP11-170L3.6 16 2.595 IGHV4-31 14 0.806 0 -inf
IGHV4-39 14 - - -
RP11-265N6.3 15 2.536 MYL12B 18 100.483 126.451 0.332
MYL12A 18 255.43 271.675 0.089
B. Under-expressed
ZNF137P 19 −3.092 ZNF816 19 4.178 3.376 −0.307
ZNF813 19 1.846 0.919 −1.007
ZNF845 19 4.772 4.083 −0.225
ZNF83 19 12.51 8.327 −0.587
FKSG61 14 6.17 6.243 0.017
SCML2P2 16 −3.003 SCMH1 1 6.914 5.049 −0.453
ANTXRLP1 10 −2.865 ANTXRL 10 0.019 0 -inf
HNRNPA3P6 3 −2.812 HNRNPA3 2 330.731 185.908 −0.831
HNRNPA1 12 1293.29 905.014 −0.515
KLHL2P1 4 −2.611 TMEM135 11 17.787 15.472 −0.201
KLHL2 4 9.699 11.424 0.236
MYB 6 87.15 78.048 −0.159
PKN1 19 25.755 27.804 0.11
CTD-2008A1.2 15 −2.58 SORD 15 25.16 12.187 −1.046
RP11-380G5.3 10 −3.463 RPL11 1 2653.49 2219.2 −0.258
RP11-114F3.5 12 −3.034 HKR1 19 17.206 12.676 −0.441
CRLF2 X 0.149 1.557 3.387
TSEN2 3 10.77 6.858 −0.651
SEPSECS 4 4.842 2.855 −0.762
MRPS25 3 31.181 28.143 −0.148
CLTA 9 24.205 34.036 0.492
RP1-224A6.8 1 −2.808 MPHOSPH6 16 22.657 22.301 −0.023
AC010733.5 2 −2.731 RPS12 6 7413.97 8991.73 0.278
RP11-411B10.4 18 −2.632 VN1R4 19 - - -
VN1R2 19 - - -
VN1R1 19 4.273 1.546 −1.466
LEPRE1 1 6.65 8.324 0.324
RP11-490K7.4 1 −2.613 GTF2A2 15 108.131 143.993 0.413
STAP2 19 19.65 20.589 0.067
STARD10 11 49.338 47.267 −0.062
ADAM10 15 37.318 21.645 −0.786
RP11-471L13.3 17 −2.608 DYNLT1 6 204.754 140.976 −0.539
DYNLT3 X 16.799 20.654 0.298
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Table 3. BLASTN hits (transcripts/splice variants) for differentially-expressed pseudogenes. Only
hits to known protein-coding genes with E-value < 10−4 and sequence similarity >90% are shown.
“fc” denotes fold change in gene expression; “Mock” represents gene expression in uninfected T-cells;
and “HIV” denotes gene expression in HIV-1-infected T-cells 7 days post-infection.
Pseudogene Chromosome log2(fc) BLASTN Hits Chromosome Mock HIV log2–(fc)
A. Over-expressed
DUTP1 3 3.869 - - - - -
UBE2FP1 3 2.595 - - - - -
MTATP8P2 2 2.59 MT-ATP8 MT 1.3e+05 1.5e+05 0.144
MT-ATP6 MT 133,475 147,477 0.144
MTND4P15 9 2.535 - - - - -
RP1-89D4.1 11 2.782 RPS24 10 6416.6 5334.27 −0.267
RP11-720N19.1 17 2.722 MSANTD3 9 9.694 9.455 −0.036
RP11-170L3.6 16 2.595 IGHVII-15-1 14 0 0 0
IGHV4-34 14 0 0 0
RP11-265N6.3 15 2.536 MYL12B 18 100.483 126.451 0.332
B. Under-expressed
ZNF137P 19 −3.092 PIGL 17 39.2801 37.686 −0.06
TBC1D9B 5 24.227 48.892 1.013
C2CD3 11 5.705 6.285 0.14
HLA-DQA1 6 47.241 35.167 −0.426
ORC6 16 14.991 19.302 0.365
SCML2P2 16 −3.003 - - - - -
ANTXRLP1 10 −2.865 ANTXRL 10 0.019 0 -inf
SOD2 6 60.695 112.151 0.886
HNRNPA3P6 3 −2.812 HNRNPA3 2 330.731 185.908 −0.831
KLHL2P1 4 −2.611 KLHL2 4 9.699 11.424 0.236
FOXK1 7 4.528 6.016 0.41
DNAJC21 5 25.755 17.957 −0.52
BIRC5 17 35.427 21.565 −0.716
TRIM59 3 70.348 43.319 −0.699
CTD-2008A1.2 15 −2.58 SORD 15 25.16 12.187 −1.046
RP11-380G5.3 10 −3.463 DOK1 2 5.483 11.781 1.104
RP11-114F3.5 12 −3.034 IDS X 2.891 3.413 0.239
AS3MT 10 20.487 16.317 −0.328
THAP6 4 7.924 4.931 −0.684
ZYG11B 1 4.275 2.514 −0.766
ABCC10 6 8.517 6.681 −0.35
RP1-224A6.8 1 −2.808 MPHOSPH6 16 22.657 22.301 −0.023
AC010733.5 2 −2.731 RPS12 6 7413.97 8991.73 0.278
RP11-411B10.4 18 −2.632 ADC 1 0.768 1.148 0.58
SLC2A5 1 0.498 0.361 −0.464
SETD2 3 12.064 9.976 −0.274
RP11-490K7.4 1 −2.613 GTF2A2 15 108.131 143.993 0.413
RP11-471L13.3 17 −2.608 DYNLT1 6 204.754 140.976 −0.539
3.2. Pseudogenes with Antagonistic Expression to the Parent Genes
If pseudogene transcripts are acting as molecular sponges for mRNA stability factors and
miRNA, then their expression will negatively correlate with that of the parent gene.
We find several pseudogene:gene pairs where pseudogene expression is antagonistic to their
BLASTX/BLASTN hits (Tables 3 and 4). The GO terms for the TBC1D9B protein product suggest its
function as a regulator of Rab-GTPase activity. Another GTPase (Rho-GTPase) is required for HIV-1
replication [44,45], but the role of Rab-GTPases in the HIV-1 life cycle is not clear. However, it has
been shown that Rab GTPase-activating proteins bind Hepatitis C virus protein NS5A to mediate
viral replication [46]. The average gene expression change from nine comparisons at 12 h and 6 h
post-infection also show upregulation of TBC1D9B and a >2-fold increase in gene expression seven
days post-infection (Table 4). Thus, the interaction between ZNF137P and TBC1D9B transcripts may
be implicated in HIV-1 replication.
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Table 4. Differentially-expressed pseudogenes in early and late HIV-1 infection. log2 (fold change)
of only those pseudogene:gene pairs are shown where the parent gene shows a >1.5-fold change
in expression due to HIV-1 infection, i.e., log2 (fold change) either >0.585 (upregulated) or <−0.585
(downregulated). The time points (12 h, 24 h or 7 days post-infection) where the genes show
a >1.5-fold change in expression are highlighted in bold. The genes that are upregulated or
downregulated in all of the replicate observations (nine observations for 12 h and six observations
for 24 h time-points) are identified by *. “on” genes are those that show detectable expression
in HIV-1-infected cells only, and “off” genes show detectable expression in uninfected cells only.
The log2 (fold change) at the 12-h and 24-h time points is the average log2 (fold change) over replicate
observations. Supplementary Table S2 lists log2 (fold change) in each replicate. ANTXRL did not have
detectable gene expression in any of the nine observations at 12 h post-infection.
Pseudogene 12 h 24 h 7 d Parent Gene 12 h 24 h 7 d
DUTP1 −0.908 on 3.869 DUT 0.245 −0.527 * −0.812
RP11-265N6.3 1.082 on 2.536 MYL12A 0.619 * −0.624 * 0.089
ZNF137P −0.031 −1.007 −3.092 TBC1D9B 0.229 0.18 * 1.013
C2CD3 −0.6 −0.21 * 0.14
ZNF813 −0.212 −0.298 * −1.007
ZNF83 0.062 0.62 * −0.587
ANTXRLP1 off −3.75 −2.865 ANTXRL - −1.086 off
HNRNPA3P6 0.406 −3.517 −2.812 HNRNPA3 −0.231 −0.962 * −0.831
HNRNPA1 −0.14 −0.903 * −0.515
KLHL2P1 on 0.017 −2.611 KLHL2 −0.043 0.79 0.236
FOXK1 −0.68 * −1.075 * 0.41
BIRC5 −0.238 −1.163 * −0.716
TRIM59 −0.1 −0.22 −0.699
MYB −0.694 * −1.915 * −0.159
CTD-2008A1.2 0.131 −0.319 −2.58 SORD 0.055 −1.928 * −1.046
RP11-380G5.3 −0.083 0.285 −3.463 DOK1 0.494 −0.252 * 1.104
RP11-114F3.5 −0.438 −0.0628 −3.034 CRLF2 −1.08 on * 3.387
TSEN2 −0.423 * −1.647 * −0.651
SEPSECS −0.003 −0.213 * −0.762
CLTA −0.05 −1.255 * 0.492
THAP6 0.474 * 0.806 * −0.684
ZYG11B −0.099 −0.093 −0.766
ABCC10 −0.594 * 0.419 * −0.35
RP1-224A6.8 0.096 on −2.808 MPHOSPH6 0.123 −0.618 * −0.023
RP11-411B10.4 0.02 −0.53 −2.632 ADC 0.24 3.235 * 0.58
SLC2A5 −1.698 1.908 * −0.464
VN1R1 0.296 * −0.425 * −1.466
RP11-490K7.4 0.346 0.069 −2.613 GTF2A2 0.031 −0.83* 0.413
ADAM10 −0.115 −0.12 −0.786
STAP2 −0.358 0.704 0.067
RP11-471L13.3 on 0.839 −2.608 DYNLT1 0.323 * 0.626 * −0.539
DYNLT3 −0.099 −0.67 * 0.298
It is known that HIV’s Tat protein downregulates SOD2 transcripts in mitochondria, leading to
mitochondria-mediated apoptosis in infected cells [47], making the pair ANTXRLP1:SOD2 of interest
(Table 3).
RP11-411B10.4’s parent gene ADC is upregulated in HIV-1 infection (more than an eight-fold
increase in gene expression at the 24-h time point; Table 4). ADC encodes arginine decarboxylase, an
enzyme that metabolizes L-arginine to agmatine. This is interesting, because increased metabolism
of L-arginine impairs lymphocyte response to antigens [48]. Thus, even though ADC expression is
not linked to HIV-1 infection, upregulation of arginine decarboxylase appears to be an effective viral
strategy to evade host immune response.
3.3. Pseudogenes with Synergistic Expression to the Parent Genes
Sometimes, pseudogene transcripts compete with the parent gene transcript for silencing
non-coding RNAs, as has been shown for tumor suppressor gene PTEN and its pseudogene
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PTENP1 [20]. Pseudogene and parent gene (or other genes with sequence similarity to the
pseudogene) expression are positively correlated under this model of pseudogene:gene interaction.
In HIV-1 infection, we find the following pseudogene:gene pairs with a positively correlated decrease
in expression: ZNF137P:ZNF813, ANTXRLP1:ANTXRL, HNRNPA3P6:HNRNPA3/HNRNPA1,
CTD-2008A1.2:SORD, KLHL2P1:BIRC5, KLHL2P1:TRIM59, KLHL2P1:MYB, RP11-114F3.5:TSEN2,
RP11-114F3.5:SEPSECS, RP11-114F3.5:ZYG11B and RP11-490K7.4:ADAM10.
Of these, only a few parent genes code for proteins that are known to have a role in viral infection,
such as HNRNPA3/HNRNPA1. The heterogeneous nuclear ribonucleoproteins (hn-RNPs) bind to
pre-mRNA and are involved in presenting the mRNA to the splicing machinery and transporting
mRNA to the cytoplasm. Downregulating hn-RNP A proteins promotes viral production due
to efficient alternative splicing of viral mRNA transcripts and their trafficking [49]. Further,
upregulation of hn-RNP A1 results in a 100-fold decline in virus production [50]. We find that
pseudogene HNRNPA3P6, its parent gene HNRNPA3 and a close paralog of the parent gene
HNRNPA1 are under-expressed in HIV-1 infection (Tables 2 and 3). It is thus possible that the
virus exploits the regulatory influence of pseudogene HNRNPA3P6 on HNRNPA3 and HNRNPA1 to
downregulate hn-RNP proteins and promote virus production.
Several functional genes similar to pseudogene KLHL2P1 are downregulated in HIV-1 infection
(Table 4). BIRC5 inhibits apoptosis, and its downregulation in both early and late HIV-1 infection
could contribute to HIV-associated depletion of T-cells [51]. While the TRIM family of proteins is
important in innate immune responses [52], we find TRIM59 to be downregulated in HIV-1 infection
(Table 4). MYB encodes a transcriptional activator protein that binds to the HIV-1 long terminal repeat
(LTR) and activates viral transcription [53]. Consistent downregulation of MYB expression could thus
be the host response to mitigate HIV-1 transcription.
Pseudogene RP11-490K7.4’s functional relative ADAM10 encodes a cell surface protein that has
both adhesion and protease domains and has been shown to facilitate nuclear trafficking of HIV-1 [54].
Another protein coding gene similar to this pseudogene, GTF2A2, is found downregulated in
uninfected T-cells in response to exposure to the HIV-1 gp120/V3 epitope [55], similar to our
observation at 24 h post-infection.
3.4. Pseudogenes and Their Parent Genes with Modulating Gene Expression in Early and
Late HIV-1 Infection
As the expression of pseudogene DUTP1 goes from a >1.5-fold decrease at 12 h post-infection to
a >8-fold increase at seven days post-infection, its parent gene expression is modulated as well from
over-expressed to under-expressed (Table 4). DUT codes for a protein that hydrolyzes the dUTP to
dUMP reaction, and its downregulation will increase cellular dUTP levels. Heavy uricilation of HIV
reverse transcripts is common and promotes chromosomal integration of the viral genome [56]. Thus,
over-expression of DUTP1 to downregulate DUT expression may be the cellular response to inhibit
the integration of uricilated viral transcripts into the host genome.
Pseudogene RP11-265N6.3 is consistently upregulated in HIV-1 infection with consistent
expression at 12 h and 24 h, and a >4-fold increase in expression at seven days post-infection.
However, its parent gene MYL12A shows modulating gene expression at 12 h and 24 h post-infection.
MYL12A is involved in the regulation of the actin cytoskeleton and is found to be upregulated
in HIV/HCV co-infection [57]. HIV-1 proteins are known to reorganize the actin cytoskeleton to
optimize virion production [58].
While pseudogene ZNF137P is increasingly downregulated as the infection progresses, its parent
gene ZNF83, an anti-inflammatory gene [59], is over-expressed by a factor of 1.5 in all six datasets
at 24 h post-infection, but is under-expressed seven days post-infection (Table 4). In contrast,
FOXK1 (parent gene of KLHL2P1) is downregulated only in early viral infection (a >1.5-fold decrease
in expression and downregulation in all nine datasets at 12 h and six datasets at the 24-h time
point; Table 4). FOXK1 inhibited interferon production in Sendai virus infection, a single-stranded
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RNA virus [60], and its downregulation in early HIV-1 infection likely contributes to triggering the
immune response.
In the RP11-114F3.5:CRLF2 pair, the CRLF2 gene shows a >2-fold downregulation 12 h
post-infection, followed by an increase in gene expression at 24 h (as reflected by the “on” signal in
all six transcriptomic comparisons at 24 h post-infection), leading to a >8-fold increase in expression
in infected cells seven days post-infection (Table 4). Thus, it appears that the CRLF2 gene expression
went from downregulated in early infection to significantly upregulated in the late HIV-1 infection.
CRLF2 encodes a receptor for cytokine TSLP, whose over-production in HIV-1 infected mucosal
epithelial cells amplifies HIV infection in activated CD4+ T-cells [61]. It is thus important to
understand how CRLF2 expression is regulated in T-cells and if pseudogene RP11-114F3.5 has any
influence on its post-transcriptional regulation.
ABCC10, a functional protein similar to pseudogene RP11-114F3.5, codes for the multidrug
resistance-associated protein 7 (MRP7) that transports molecules, such as xenobiotics, across intra-
and extra-cellular membranes [62]. HIV-Tat is known to upregulate the expression of another
transporter from the same family (MRP1), a cell-surface protein of the cells of the blood brain
barrier that remove anti-viral drugs from the central nervous system [63]. It is thus likely that
modulating gene expression of ABCC10 (downregulated in all nine datasets at 12 h and upregulated
in all six datasets at 24 h post-infection) might be interfering with the transport of molecules across
HIV-1-infected T-cells. Interestingly, another transporter encoding gene (SLC2A5) shows modulating
gene expression, as well (a >3-fold decrease in expression at 12 h and a >3-fold increase in expression
at the 24-h time point; Table 4).
Pseudogene RP11-471L13.3 is over-expressed by a factor of >1.5 at 24 h and shows a >4-fold
decrease in expression seven days post-infection. Its putative parents genes (DYNLT1 and DYNLT3)
are dynein motor proteins that carry cargo, such as proteins, across the cellular microtubules; dynein
proteins are thought to associate with viral proteins during infections [64].
Other pseudogene:gene pairs with modulating gene expression in early and late HIV-1 infection,
but with unknown roles in viral infection, are RP11-380G5.3:DOK1 and RP11-114F3.5:THAP6.
4. Discussion
Although Vanin characterizes pseudogenes as “related but defective” [22], this sentiment
has seen a shift in recent years. With the accumulating evidence of functional consequences of
pseudogene transcription, the term “pseudogene” should be revisited [1]. A pseudogene capable
of exerting regulatory control on other genes via its RNA intermediates is functionally active even if
it does not code for a protein. Although most pseudogenes are thought to evolve neutrally [3,65],
some transcribed pseudogenes exhibit patterns of non-neutral evolution [66]. The contribution
of pseudogenes to the non-coding small-RNA pool that regulates the expression of a wide range
of genes provides a possible explanation for their evolutionary maintenance. About a fifth of
human pseudogenes are transcribed [3], and thus might be candidates for purifying selection if they
participate in gene expression regulation. For a retrovirus with a pre-packaged reverse transcriptase
and integrase, this presents an opportunity to exploit a layer of gene expression regulation for its own
benefit. Here, we present evidence that suggests the involvement of pseudogenes in the regulation of
cellular gene expression in the early stages of a retroviral infection.
Our computational pipeline for detecting differentially-expressed pseudogenes relies on
software that is widely used and accepted by the scientific community. Gene expression is normalized
by gene length to account for the fact that longer genes end up producing more sequencing reads
than shorter genes. Although it is desirable to have replicates in the sequencing experiment design,
replicate data are usually generated by pooling the replicate samples together in a single sequencing
run, reducing the data generated per sample. While we analyzed multiple replicate transcriptomes at
12 h and 24 h post-infection (which likely increased specificity) the single transcriptome at seven
days post-infection time point had four times the sequencing data (≈80 million reads compared
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to the ≈20 million reads at the 12-h and 24-h time points). This high sequencing depth combined
with high quality reads and a mean fragment size of >350 (150 × 2 paired-end sequencing) for both
uninfected and infected samples improves sensitivity in detecting differentially-expressed genes and
adds confidence to our predictions. Both increasing sequencing depth and biological replication
have been shown to increase the power of detecting differentially-expressed genes [67]. Strongly
upregulated protein-coding genes in our data (the seven-day time point) are implicated in HIV-1
infection, lending further confidence to our analysis (Supplementary Table S1).
While our methodology cannot find novel pseudogenes that might be created in an infected
cell due to viral reverse transcriptase and integrase activity, we find a small number of known
pseudogenes that are differentially expressed in HIV-1-infected cells. While the data from the 12-h
and 24-h time points comes from a T lymphocyte cell-line that is different from the T-cell-line at
the seven-day time point, our candidate pseudogene:gene interactions show consistent differential
expression across the three time points, suggesting that these host responses are not cell-line specific.
We further identify protein-coding genes (parent genes or genes that are BLASTX/BLASTN hits to the
pseudogenes) whose expression is correlated with that of the differentially-expressed pseudogenes.
One third of these parent genes are implicated in HIV-1 infection, suggesting pseudogene-mediated
post-transcriptional regulation of gene expression in the infected cells. It should be noted that
the study that experimentally confirmed the effect of pseudogene PTENP1 transcription on the
mRNA levels of tumor suppressor gene parent gene PTEN showed that the change in PTEN
mRNA expression was less than two-fold, yet the pseudogene PTENP1 is “selectively lost in human
cancer” [20]. Thus, we restricted our focus to those parent genes that show a >1.5-fold change in
gene expression at 12 h, or 24 h, or seven days post-infection (Table 4). It is possible that these
parent genes are differentially expressed in HIV-1 infection due to other factors in the complex
gene-regulatory machinery of the cell, but the significant change in expression in their pseudogenes
suggests pseudogene-mediated gene expression regulation. Experimental validation of regulatory
interactions between the candidate pseudogene:gene pairs is needed to confirm if viruses exploit this
newly-discovered layer of post-transcriptional regulation of gene expression.
5. Conclusions
In this study, we find that instead of being silent spectators, pseudogenes are differentially
expressed in HIV-1 infection. While non-coding RNAs are now considered integral to the host
response to viral infections, our findings indicate for the first time that RNAs derived from
pseudogene transcripts are a part of the cellular non-coding RNA pool, and may regulate expression
of genes implicated in viral infections. Functional relevance of pseudogene transcription has been
experimentally verified in cancer but remains to be validated in viral infections. We anticipate that
pseudogene transcription will be of significance in other cellular processes and in host responses to
the environment as well.
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